Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis

Journal of Psychiatric Research

Volumn 33, Issue 5, 1999, Pages 407-418

  Haack, M ^a   Hinze Selch, D ^a   Fenzel, T ^a   Kraus, T ^a   Kuhn M ^a   Schuld, A ^a   Pollmacher T ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Age; Body mass index; Cytokines; Gender; Infection; Major depression; Psychotropic medication; Schizophrenia; Smoking

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOZAPINE; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; LITHIUM; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; DEPRESSION; DRUG THERAPY; EPIDEMIOLOGY; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFECTION; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL PATIENT; MULTIPLE REGRESSION; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING HABIT;

CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; MENTAL DISORDERS; PATIENT ADMISSION; PSYCHONEUROIMMUNOLOGY; PSYCHOTROPIC DRUGS; RECEPTORS, CYTOKINE; REFERENCE VALUES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032790648     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(99)00021-7     Document Type: Article

References (95)

1. Arena A., Capozza A.B., Orlando M.E., Currò F., Losi E., Chillemi S., Mesiti M., Merendino R.A. In vitro effects of lithium chloride on TNFα and IL-6 production by monocytes from breast cancer patients. Journal of Chemotherapy. 9:1997;219-226.
2. Argilés J.M., López-Soriano J., Busquets S., López-Soriano F.J. Journey from cachexia to obesity by TNF. FASEB Journal. 11:1997;743-751.
3. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophrenia Research. 20:1996;199-203.
4. Barak V., Barak Y., Levine J., Nisman B., Roisman I. Changes in interleukin-1β and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. Journal of Basic and Clinical Physiology and Pharmacology. 6:1995;61-69.
5. Bessler H., Levental Z., Karp L., Modai I., Djaldetti M., Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biological Psychiatry. 38:1995;297-302.
6. Born J., Uthgenannt D., Dodt C., Nünninghoff D., Ringvolt E., Wagner T., Fehm H.L. Cytokine production and lymphocyte subpopulations in aged humans. An assessment during nocturnal sleep. Mechanisms of Ageing and Development. 84:1995;113-126.
7. Brambilla F., Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatrica Scandinavica. 97:1998;309-313.
8. Catania A., Airaghi L., Motta P., Manfredi M.G., Annoni G., Pettenati C., Brambilla F., Lipton J.M. Cytokine antagonists in aged subjects and their relation with cellular immunity. Journals of Gerontology: Medical Sciences. 52A:1997;B93-B97.
9. Chrousos G.P. Seminars in medicine of the Beth Israel hospital, Boston - the hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New England Journal of Medicine. 332:1995;1351-1362.
10. Cohen H.J., Pieper C.F., Harris T., Rao K.M.K., Currie M.S. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. Journals of Gerontology: Medical Sciences. 52A:1997;M201-M208.
11. Covey L.S., Glassman A.H., Stetner F. Cigarette smoking and major depression. Archives of General Psychiatry. 17:1998;35-46.
12. Darko D.F., Lucas A.H., Gillin J.C., Risch S.C., Golshan S., Hamburger R.N., Silverman M.B., Janowsky D.S. Cellular immunity and the hypothalamic-pituitary axis in major affective disorder: a preliminary study. Psychiatry Research. 25:1988;1-9.
13. de Leon J., Dadvand M., Canuso C., White A.O., Stanilla J.K., Simpson G.M. Schizophrenia and smoking: an epidemiological survey in a state hospital. American Journal of Psychiatry. 152:1995;453-455.
14. Elmquist J.K., Scammell T.E., Saper C.B. Mechanisms of CNS response to systemic immune challenge: the febrile response. Trends in Neurosciences. 20:1997;565-570.
15. Frommberger U.H., Bauer J., Haselbauer P., Fräulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. European Archives of Psychiatry and Clinical Neuroscience. 247:1997;228-233.
16. Ganguli R., Rabin B.S. Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects. Archives of General Psychiatry. 46:1989;292.
17. Ganguli R., Rabin B.S., Belle S.H. Decreased interleukin-2 production in schizophrenic patients. Biological Psychiatry. 26:1989;427-430.
18. Ganguli R., McAllister C.G., Rabin B.S., Solomon W. Alterations in interleukins and in T lymphocyte subsets in a subgroup of schizophrenics. Biological Psychiatry. 29:1991;109A.
19. Ganguli R., Brar J.S., Solomon W., Chengappa K.N., Rabin B.S. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Research. 44:1992;113-123.
20. Ganguli R., Yang Z., Shurin G., Chengappa K.N., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research. 51:1994;1-10.
21. Ganguli R., Brar J.S., Chengappa K.R., DeLeo M., Yang Z.W., Shurin G., Rabin B.S. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Archives of General Psychiatry. 52:1995;668-672.
22. Haenen R., Moens G., Jacques P. The prevalence of infections in psychiatric institutes in Belgium. Journal of Hospital Infection. 37:1997;273-280.
23. Hopkins S.J., Rothwell N.J. Cytokines and the nervous system. I. Expression and recognition. Trends in Neurosciences. 18:1995;83-88.
24. Hornberg M., Arolt V., Wilke I., Kruse A., Kirchner H. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophrenia Research. 15:1995;237-242.
25. Kanba S., Manki H., Shintani F., Ohno Y., Yagi G., Asai M. Aberrant interleukin-2 receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode. Psychological Medicine. 28:1998;481-484.
26. Katila H., Appelberg B., Hurme M., Rimón R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses and affective disorders. Schizophrenia Research. 12:1994;29-34.
27. Katila H., Hurme M., Wahlbeck K., Appelberg B., Rimón R. Plasma and cerebrospinal fluid interleukin-1β and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology. 30:1994;20-23.
28. Katsuki A., Sumida Y., Murashima S., Murata K., Takarada Y., Ito K., Fujii M., Tsuchihashi K., Goto H., Nakatani K., Yano Y. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 83:1998;859-862.
29. Kim Y.K., Lee M.S., Suh K.Y. Decreased interleukin-2 production in Korean schizophrenic patients. Biological Psychiatry. 43:1998;701-704.
30. King A.J., Kehayias J.J., Roubenoff R., Schmid C.H., Pereira B.J. Cytokine production and nutritional status in hemodialysis patients. International Journal of Artificial Organs. 21:1998;4-11.
31. Kleinerman E.S., Knowles R.D., Blick M.B., Zwelling L.A. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin. Journal of Leukocyte Biology. 46:1989;484-492.
32. Landmann R., Schaub B., Link S., Wacker H.R. Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biological Psychiatry. 41:1997;675-681.
33. Lucey D.R., Clerici M., Shearer G.M. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic and inflammatory diseases. Clinical Microbiology Reviews. 9:1996;532-562.
34. Lynch E.A., Dinarello C.A., Cannon J.G. Gender differences in IL-1α, IL-1β and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. Journal of Immunology. 153:1994;300-306.
35. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica. 89:1994;346-351.
36. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. Journal of Psychiatric Research. 29:1995;141-152.
37. Maes M., Bosmans E., Meltzer H.Y. Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. European Archives of Psychiatry and Clinical Neuroscience. 245:1995;172-178.
38. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders. 34:1995;301-309.
39. Maes M., Meltzer H.Y., Buckley P., Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. European Archives of Psychiatry and Clinical Neuroscience. 244:1995;325-329.
40. Maes M., Vandoolaeghe E., Ranjan R., Bosmans E., Bergmans R., Desnyder R. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. Journal of Affective Disorders. 36:1995;29-36.
41. Maes M., Bosmans E., de Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 9:1997;853-858.
42. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia Research. 26:1997;221-225.
43. McDonald E.M., Mann A.H., Thomas H.C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant α-interferon in hepatitis-B carriers. Lancet. 2:1987;1175-1178.
44. Mendall M.A., Patel P., Asante M., Ballam L., Morris J., Strachan D.P., Camm A.J., Northfield T.C. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 78:1997;273-277.
45. Merendino R.A., Mancuso G., Tomasello F., Gazzara D., Cusumano V., Chillemi S., Spadaro P., Mesiti M. Effects of lithium carbonate on cytokine production in patients affected by breast cancer. Journal of Biological Regulators and Homeostatic Agents. 8:1994;88-91.
46. Monteleone P., Fabrazzo M., Tortorella A., Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Research. 71:1997;11-17.
47. Naudin J., Mège J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophrenia Research. 20:1996;269-273.
48. Naudin J., Capo C., Giusano B., Mège J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophrenia Research. 26:1997;227-233.
49. Niiranen A., Laaksonen R., Iivanainen M., Mattson K., Färkkilä M., Cantell K. Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatrica Scandinavica. 78:1988;622-626.
50. Paganelli R. Humoral immunity in aging. Aging. 6:1994;143-150.
51. Pollmächer T., Mullington J., Korth C., Hinze-Selch D. Influence of host defense activation on sleep in humans. Advances in Neuroimmunology. 5:1995;155-169.
52. Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. Journal of Clinical Psychopharmacology. 16:1996;403-409.
53. Pollmächer T., Korth C., Mullington J., Schreiber W., Sauer J., Vedder H., Galanos C., Holsboer F. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood. 87:1996;900-905.
54. Pollmächer T., Fenzel T., Mullington J., Hinze-Selch D. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels. Pharmacopsychiatry. 30:1997;118-121.
55. Pollmächer T., Hinze-Selch D., Fenzel T., Kraus T., Schuld A., Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. American Journal of Psychiatry. 154:1997;1763-1765.
56. Pollmächer T., Hinze-Selch D., Mullington J., Fenzel T., Holsboer F. Smoking affects plasma-soluble interleukin-2 receptor levels in patients with schizophrenia. Archives of General Psychiatry. 54:1997;89.
57. Rapaport M.H., McAllister C.G., Pickar D., Nelson D.L., Paul S.M. Elevated levels of soluble interleukin 2 receptors in schizophrenia. Archives of General Psychiatry. 46:1989;291-292. [letter].
58. Rapaport M.H., Torrey E.F., McAllister C.G., Nelson D.L., Pickar D., Paul S.M. Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. European Archives of Psychiatry and Clinical Neuroscience. 243:1993;7-10.
59. Rapaport M.H., Lohr J.B. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatrica Scandinavica. 90:1994;311-315.
60. Rapaport M.H., McAllister C.G., Kim Y.S., Han J.H., Pickar D., Nelson D.L., Kirch D.G., Paul S.M. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biological Psychiatry. 35:1994;767-771.
61. Rapaport M.H., Schmidt M.E., Risinger R., Manji H. The effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. Biological Psychiatry. 35:1994;761-766.
62. Rossano F., Tufano R., Cipollaro de L'Ero G., Servillo G., Baroni A., Tufano M.A. Anesthetic agents induce human mononuclear leucocytes to release cytokines. Immunopharmacology and Immunotoxicology. 14:1992;439-450.
63. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., Kirchner H. Production of cytokines in acute schizophrenic psychosis. Biological Psychiatry. 40:1996;1294-1297.
64. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology. 37:1998;186-193.
65. Rothwell N.J., Hopkins S.J. Cytokines and the nervous system. II. Actions and mechanisms of action. Trends in Neurosciences. 18:1995;130-136.
66. Roubenoff R., Harris T.B., Abad L.W., Wilson P.W.F., Dallal G.E., Dinarello C.A. Monocyte cytokine production in an elderly population: effect of age and inflammation. Journals of Gerontology: Medical Sciences. 53A:1998;M20-M26.
67. Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor: biology, function and clinical application. Annals of Internal Medicine. 113:1990;619-627.
68. Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warzocha K., Gutowski M.C., Rieux C., Coiffier B. Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. British Journal of Haematology. 93:1996;352-359.
69. Schattner A., Cori Y., Hahn T., Sirota P. No evidence for autoimmunity in schizophrenia. Journal of Autoimmunity. 9:1996;661-666.
70. Schuld A, Mullington J, Hermann D, Hinze-Selch D, Fenzel T, Holsboer F, Pollmächer T. Effects of granulocyte colony-stimulating factor on sleep in humans. American Journal of Physiology 1999;276:121149-55.
71. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Cytokine production and serum proteins in depression. Scandinavian Journal of Immunology. 41:1995;534-538.
72. Shintani F., Kanba S., Maruo N., Nakaki T., Nibuya M., Suzuki E., Kinoshita N., Yagi G. Serum interleukin-6 in schizophrenic patients. Life Sciences. 49:1991;661-664.
73. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Research. 64:1996;161-167.
74. Smith R.S. The macrophage theory of depression. Medical Hypotheses. 35:1991;298-306.
75. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Medical Hypotheses. 45:1995;135-141.
76. Song C., Lin A.H., Bonaccorso S., Heide C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Whelan A., Cosyns P., de Jongh R., Maes M. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. Journal of Affective Disorders. 49:1998;211-219.
77. Späth-Schwalbe E., Hansen K., Schmidt F., Schrezenmeier H., Marshall L., Burger K., Fehm H.L., Born J. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. Journal of Clinical Endocrinology and Metabolism. 83:1998;1573-1579.
78. Spriggs D.R., Sherman M.L., Michie H., Arthur K.A., Imamura K., Wilmore D., Frei E., Kufe D.W. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. Journal of the National Cancer Institute. 80:1988;1039-1044.
79. Standiford T.J. Cytokines and pulmonary host defenses. Current Opinion in Pulmonary Medicine. 3:1997;81-88.
80. Stefanis C.N., Theodoropoulou-Vaidaki S., Baxevanis C.N., Spanakos G., Papadopoulos N.G., Economou M. Investigation of immune parameters in never medicated and chronically medicated schizophrenic patients. Neuropsychopharmacology. 10:1994;385S.
81. Tappia P.S., Troughton K.L., Langley-Evans S.C., Grimble R.F. Cigarette smoking influences cytokine production and antioxidant defences. Clinical Science. 88:1995;485-489.
82. Taupin V., Jayais P., Descamps-Latscha B., Cazalaa J.B., Barrier G., Bach J.F., Zavala F. Benzodiazepine anesthesia in humans modulates the interleukin-1β, tumor necrosis factor-α and interleukin-6 responses of blood monocytes. Journal of Neuroimmunology. 35:1991;13-19.
83. Tollerud D.J., Kurman C.C., Nelson D.L., Brown L.M., Maloney E.M., Blattner W.A. Racial variation in serum-soluble interleukin-2 receptor levels: a population-based study of healthy smokers and nonsmokers. Clinical Immunology and Immunopathology. 70:1994;274-279.
84. Turnbull A.V., Rivier C. Regulation of the HPA axis by cytokines. Brain, Behavior and Immunity. 9:1995;253-275.
85. van der Poll T., Lowry S.F. Tumor necrosis factor in sepsis - mediator of multiple organ failure or essential part of host defense. Shock. 3:1995;1-12.
86. Villemain F., Chatenoud L., Galinowski A., Homo-Delarche F., Ginestet D., Loo H., Zarifian E., Bach J.F. Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. American Journal of Psychiatry. 146:1989;609-616.
87. Walker L.G., Walker M.B., Heys S.D., Lolley J., Wesnes K., Eremin O. The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psycho-Oncology. 6:1997;290-301.
88. Wei J., Xu H.M., Davies J., Ramchand C.N., Ramchand R., Hemmings G.P. Interleukins 1, 2 and 6 in the plasma of neuroleptic-free and treated schizophrenic patients and their relatives. Schizophrenia Research. 6:1992;140.
89. Wei J., Xu H., Davies J.L., Hemmings G.P. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sciences. 51:1992;1953-1956.
90. Weizman R., Laor N., Podliszewski E., Notti I., Djaldetti M., Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biological Psychiatry. 35:1994;42-47.
91. Wilke I., Arolt V., Rothermundt M., Weitzsch C., Hornberg M., Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience. 246:1996;279-284.
92. Xu H.M., Wei J., Hemmings G.P. Changes of plasma concentrations of interleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia. British Journal of Psychiatry. 164:1994;251-253.
93. Yolken R.H., Torrey E.F. Viruses, schizophrenia and bipolar disorder. Clinical Microbiology Reviews. 8:1995;131-145.
94. Zavala F., Taupin V., Descamps-Latscha B. In vivo treatment with benzodiazepines inhibits murine phagocyte oxidative metabolism and production of interleukin 1, tumor necrosis factor and interleukin-6. Journal of Pharmacology and Experimental Therapeutics. 255:1990;442-450.
95. Zhao S.P., Zeng L.H. Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. International Journal of Cardiology. 58:1997;257-261.